Hepatitis B

Study shows effectiveness of hepatitis B treatment

Published in Women's Health Weekly, July 28th, 2005

According to a major study published in the New England Journal of Medicine, patients with the most common form of hepatitis B in the United States who are treated with PEGASYS (peginterferon alfa-2a), the market-leading treatment for hepatitis C, are more likely to achieve a sustained response than those treated with lamivudine, the current standard of care.

The results indicate that PEGASYS offers a unique therapeutic option for patients with chronic hepatitis B, and unlike oral treatment options, offers patients a defined period of therapy.

In the phase III study, conducted by Roche, patients treated with PEGASYS displayed improvement in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2005-07-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry